Scientific and Medical Advisors
Dr. Block is Co-Founder and President of the Baruch S. Blumberg Institute and the Hepatitis B Foundation, which established the Institute in 2003 to advance its research mission to find a cure for hepatitis B. He has been involved in hepatitis research for more than 25 years and is internationally recognized for his scholarship and scientific contributions to the field. Dr. Block was a tenured Professor at Thomas Jefferson University for 20 years and at Drexel University College of Medicine for 10 years.
Dr. Mehta is SmartState Endowed Chair of Proteomic Biomarkers and Professor, Medical University of South Carolina. He received his graduate degree in Biochemistry from the University of Oxford under the supervision of Professor Raymond Dwek and Noble Laureate Baruch Blumberg. While a student at the University of Oxford, Dr. Mehta examined methods by which viruses form and developed methods to inhibit them. Several compounds that Dr. Mehta developed are currently under commercial development as antivirals for the treatment of Dengue, Influenza, Ebola and Marburg Virus. As the Bruce Witte Scholar of the Hepatitis B Foundation, Dr. Mehta’s laboratory focused developing diagnostic tools and treatments for hepatocellular carcinoma (HCC). Dr. Mehta developed a method referred to as glycoproteomics to identify biomarkers of HCC. Dr. Mehta is a member of the National Cancer Institute’s Alliance of Glycobiologists for Cancer Detection and the Early Detection Research Network. Funding for his laboratory is from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases and the National Institute on Alcohol Abuse and Alcoholism.
Dr. Chernoff has served as acting Chief Medical Officer for several start-up molecular diagnostic companies including XDx, CardioDx, and Tethys Bioscience. Previously, he was Vice President of Corporate Technology at Elan Pharmaceuticals and Medical Director of Chiron Diagnostics, where he played a pivotal role in the development of assays for HIV, HCV, HBV, and CMV. He recently spent two years as an Entrepreneur-in-Residence and one year as an Operating Partner at the venture firm TPG. Dr. Chernoff holds an MD from New York University and completed his medical training in internal medicine, rheumatology, and infectious disease at the University of California, San Francisco.
Scott Friedman is Chief of the Division of Liver Diseases and Dean for Therapeutic Discovery at the Icahn School of Medicine at Mount Sinai, New York and was President of the American Association for the Study of Liver Diseases (AASLD) in 2009. Dr. Friedman is one of the foremost leaders in the field of liver fibrosis, having been the first to isolate and characterise the causative cell type. He contributes a wealth of experience with emerging diagnostic and therapeutic approaches in serious liver disease. Dr. Friedman received his MD degree from Mount Sinai and completed his training at Beth Israel Hospital, Boston and the University of California, San Francisco.
Douglas Dieterich is Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York with appointments in the Divisions of Liver Diseases, Gastroenterology and Infectious Diseases, and is the newly appointed Director for the Institute for Liver Medicine at the Mount Sinai Health System. Chronic hepatitis B and C are key focal areas of Dr. Dieterich’s clinical research and he has authored many publications on viral hepatitis and AIDS-related infections of the liver. His extensive clinical practice experience in serious liver disease will be a vital resource for Glycotest. Dr. Dieterich’s MD degree is from New York University School of Medicine and he completed his medical training at Bellevue Hospital Center in New York.